Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting
2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (FDG PET/CT) has an established clinical value in the diagnosis and initial staging of multiple myeloma (MM). In the last ten years, a vast body of literature has shown that this tool can also be of high relevance...
Main Authors: | Giulia Ferrarazzo, Silvia Chiola, Selene Capitanio, Maria Isabella Donegani, Alberto Miceli, Stefano Raffa, Alberto Stefano Tagliafico, Silvia Morbelli, Matteo Bauckneht |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/2/230 |
Similar Items
-
Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology
by: Maria Isabella Donegani, et al.
Published: (2020-07-01) -
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
by: Christos Sachpekidis, et al.
Published: (2019-12-01) -
Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
by: Maria Isabella Donegani, et al.
Published: (2021-03-01) -
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma
by: Silvia Valtorta, et al.
Published: (2021-10-01) -
Beyond the Prognostic Value of 2-[<sup>18</sup>F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
by: Roberto Borea, et al.
Published: (2022-02-01)